The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets

Seminars in Cancer Biology

Volumn 21, Issue 1, 2011, Pages 35-43

  Yang, Ju Dong ^a   Nakamura, Ikuo ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer associated fibroblast; Gene signature; Hepatic stellate cells; Hepatocellular carcinoma; Inflammatory cytokine; Kupffer cell; Matrix metalloproteinase; T cell; TGF 1; Tissue inhibitor of metalloproteinase; Treatment; Tumor microenvironment

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTINEOPLASTIC AGENT; AVE 1642; BEVACIZUMAB; BIIB 022; BRIVANIB; CEDIRANIB; CETUXIMAB; CIXUTUMUMAB; CONNECTIVE TISSUE GROWTH FACTOR; CT 011; E 7080; E7080; ERLOTINIB; GC 33; INTEDANIB; LINIFANIB; MEDI 575; PI 88; PLATELET DERIVED GROWTH FACTOR; PRAVASTATIN; RAMUCIRUMAB; REGORAFENIB; SCLEROPROTEIN; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VANDETANIB; XL 184;

CANCER CLASSIFICATION; CANCER GROWTH; CELL ACTIVITY; CELL INTERACTION; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; FIBROBLAST; FIBROGENESIS; GENE EXPRESSION PROFILING; HUMAN; INTRACELLULAR SIGNALING; KUPFFER CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STELLATE CELL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 79952038728     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.10.007     Document Type: Review

References (136)

1. GLOBOCAN 2008.
2. Tang D.J., Dong S.S., Ma N.F., Xie D., Chen L., Fu L., et al. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology 2010, 51:1255-1263.
3. Bruix J., Boix L., Sala M., Llovet J.M. Focus on hepatocellular carcinoma. Cancer Cell 2004, 5:215-219.
4. Amann T., Bataille F., Spruss T., Muhlbauer M., Gabele E., Scholmerich J., et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009, 100:646-653.
5. Nitta T., Kim J.S., Mohuczy D., Behrns K.E. Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 2008, 48:909-919.
6. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
7. Zeisberg M., Yang C., Martino M., Duncan M.B., Rieder F., Tanjore H., et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007, 282:23337-23347.
8. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428.
9. Friedman S.L., Roll F.J., Boyles J., Bissell D.M. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985, 82:8681-8685.
10. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
11. Sokolovic A, Sokolovic M, Boers W, Elferink RP, Bosma PJ. Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells. Fibrogenesis Tissue Repair 2010; 3:3.
12. Bachem M.G., Meyer D., Melchior R., Sell K.M., Gressner A.M. Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblast like cells. A potential mechanism of self perpetuation in liver fibrogenesis. J Clin Invest 1992, 89:19-27.
13. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008, 88:125-172.
14. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
15. Friedman S.L. Liver fibrosis-from bench to bedside. J Hepatol 2003, 38(Suppl 1):S38-S53.
16. Dubuisson L., Lepreux S., Bioulac-Sage P., Balabaud C., Costa A.M., Rosenbaum J., et al. Expression and cellular localization of fibrillin-1 in normal and pathological human liver. J Hepatol 2001, 34:514-522.
17. Campbell J.S., Hughes S.D., Gilbertson D.G., Palmer T.E., Holdren M.S., Haran A.C., et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005, 102:3389-3394.
18. Eghbali-Fatourechi G., Sieck G.C., Prakash Y.S., Maercklein P., Gores G.J., Fitzpatrick L.A. Type I procollagen production and cell proliferation is mediated by transforming growth factor-beta in a model of hepatic fibrosis. Endocrinology 1996, 137:1894-1903.
19. Roderfeld M., Weiskirchen R., Wagner S., Berres M.L., Henkel C., Grotzinger J., et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. Faseb J 2006, 20:444-454.
20. Kluwe J., Pradere J.P., Gwak G.Y., Mencin A., De Minicis S., Osterreicher C.H., et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010, 138:347-359.
21. Moles A., Tarrats N., Fernandez-Checa J.C., Mari M. Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology 2009, 49:1297-1307.
22. Martin-Vilchez S., Sanz-Cameno P., Rodriguez-Munoz Y., Majano P.L., Molina-Jimenez F., Lopez-Cabrera M., et al. The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. Hepatology 2008, 47:1872-1883.
23. Schulze-Krebs A., Preimel D., Popov Y., Bartenschlager R., Lohmann V., Pinzani M., et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005, 129:246-258.
24. Kamada Y., Matsumoto H., Tamura S., Fukushima J., Kiso S., Fukui K., et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007, 47:556-564.
25. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401.
26. Ostman A., Augsten M. Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. Curr Opin Genet Dev 2009, 19:67-73.
27. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010, 316:1324-1331.
28. Fransvea E., Mazzocca A., Antonaci S., Giannelli G. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 2009, 49:839-850.
29. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
30. Gao Q., Qiu S.J., Fan J., Zhou J., Wang X.Y., Xiao Y.S., et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25:2586-2593.
31. Fu J., Xu D., Liu Z., Shi M., Zhao P., Fu B., et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132:2328-2339.
32. Gajewski T.F., Meng Y., Blank C., Brown I., Kacha A., Kline J., et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006, 213:131-145.
33. Chew V., Tow C., Teo M., Wong H.L., Chan J., Gehring A., et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010, 52:370-379.
34. Barajas M., Mazzolini G., Genove G., Bilbao R., Narvaiza I., Schmitz V., et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 2001, 33:52-61.
35. Wu K., Kryczek I., Chen L., Zou W., Welling T.H. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 2009, 69:8067-8075.
36. Benedicto I., Molina-Jimenez F., Barreiro O., Maldonado-Rodriguez A., Prieto J., Moreno-Otero R., et al. Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology 2008, 48:1044-1053.
37. Ramaiah S.K., Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 2008, 103:4-13.
38. Benetti A., Berenzi A., Gambarotti M., Garrafa E., Gelati M., Dessy E., et al. Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. Cancer Res 2008, 68:8626-8634.
39. Xiong Y.Q., Sun H.C., Zhang W., Zhu X.D., Zhuang P.Y., Zhang J.B., et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 2009, 15:4838-4846.
40. Zhang T., Sun H.C., Xu Y., Zhang K.Z., Wang L., Qin L.X., et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 2005, 11:8557-8563.
41. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176.
42. Bedossa P., Peltier E., Terris B., Franco D., Poynard T. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995, 21:760-766.
43. Gao R., Brigstock D.R. Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J Biol Chem 2004, 279:8848-8855.
44. Gomis R.R., Alarcon C., Nadal C., Van Poznak C., Massague J. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 2006, 10:203-214.
45. Massague J. TGFbeta in Cancer. Cell 2008, 134:215-230.
46. Siegel P.M., Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003, 3:807-821.
47. Murata M., Matsuzaki K., Yoshida K., Sekimoto G., Tahashi Y., Mori S., et al. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 2009, 49:1203-1217.
48. Matsuzaki K., Murata M., Yoshida K., Sekimoto G., Uemura Y., Sakaida N., et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007, 46:48-57.
49. Sohn B.H., Park I.Y., Lee J.J., Yang S.J., Jang Y.J., Park K.C., et al. Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter. Gastroenterology 2010, 138:1898-1908.
50. Spagnoli F.M., Cicchini C., Tripodi M., Weiss M.C. Inhibition of MMH (Met murine hepatocyte) cell differentiation by TGF(beta) is abrogated by pre-treatment with the heritable differentiation effector FGF1. J Cell Sci 2000, 113(Pt 20):3639-3647.
51. Giannelli G., Bergamini C., Fransvea E., Sgarra C., Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005, 129:1375-1383.
52. Peinado H., Quintanilla M., Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003, 278:21113-21123.
53. Fransvea E., Angelotti U., Antonaci S., Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008, 47:1557-1566.
54. Giannelli G., Fransvea E., Marinosci F., Bergamini C., Colucci S., Schiraldi O., et al. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 2002, 161:183-193.
55. Katabami K., Mizuno H., Sano R., Saito Y., Ogura M., Itoh S., et al. Transforming growth factor-beta1 upregulates transcription of alpha3 integrin gene in hepatocellular carcinoma cells via Ets-transcription factor-binding motif in the promoter region. Clin Exp Metastasis 2005, 22:539-548.
56. Mazzocca A., Fransvea E., Lavezzari G., Antonaci S., Giannelli G. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 2009, 50:1140-1151.
57. Mazzocca A., Fransvea E., Dituri F., Lupo L., Antonaci S., Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 2010, 51:523-534.
58. van Zijl F., Mair M., Csiszar A., Schneller D., Zulehner G., Huber H., et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 2009, 28:4022-4033.
59. Wang B., Hsu S.H., Majumder S., Kutay H., Huang W., Jacob S.T., et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010, 29:1787-1797.
60. Huang S., He X., Ding J., Liang L., Zhao Y., Zhang Z., et al. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer 2008, 123:972-978.
61. Yang J.C., Teng C.F., Wu H.C., Tsai H.W., Chuang H.C., Tsai T.F., et al. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 2009, 49:1962-1971.
62. Ogasawara S., Yano H., Iemura A., Hisaka T., Kojiro M. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 1996, 24:198-205.
63. Neaud V., Faouzi S., Guirouilh J., Le Bail B., Balabaud C., Bioulac-Sage P., et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 1997, 26:1458-1466.
64. Liu L.P., Liang H.F., Chen X.P., Zhang W.G., Yang S.L., Xu T., et al. The role of NF-kappaB in Hepatitis b virus X protein-mediated upregulation of VEGF and MMPs. Cancer Invest 2010, 28:443-451.
65. Gurtner G.C., Werner S., Barrandon Y., Longaker M.T. Wound repair and regeneration. Nature 2008, 453:314-321.
66. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16:159-178.
67. Lai J.P., Chien J.R., Moser D.R., Staub J.K., Aderca I., Montoya D.P., et al. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 2004, 126:231-248.
68. Gross J., Lapiere C.M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 1962, 48:1014-1022.
69. Parks W.C., Wilson C.L., Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004, 4:617-629.
70. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010.
71. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
72. Yu Q., Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999, 13:35-48.
73. Cheng J.C., Chou C.H., Kuo M.L., Hsieh C.Y. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 2006, 25:7009-7018.
74. Chen J.S., Wang Q., Fu X.H., Huang X.H., Chen X.L., Cao L.Q., et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 2009, 39:177-186.
75. Mitsiades N., Yu W.H., Poulaki V., Tsokos M., Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001, 61:577-581.
76. Littlepage L.E., Sternlicht M.D., Rougier N., Phillips J., Gallo E., Yu Y., et al. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 2010, 70:2224-2234.
77. Kohga K., Tatsumi T., Takehara T., Tsunematsu H., Shimizu S., Yamamoto M., et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol 2010, 52:872-879.
78. Manicone A.M., McGuire J.K. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008, 19:34-41.
79. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117:1175-1183.
80. Arii S., Mise M., Harada T., Furutani M., Ishigami S., Niwano M., et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 1996, 24:316-322.
81. Takafuji V., Forgues M., Unsworth E., Goldsmith P., Wang X.W. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007, 26:6361-6371.
82. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
83. Woo H.G., Park E.S., Cheon J.H., Kim J.H., Lee J.S., Park B.J., et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 2008, 14:2056-2064.
84. Ou D.P., Tao Y.M., Tang F.Q., Yang L.Y. The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. Int J Cancer 2007, 120:1208-1214.
85. Yu F.L., Liu H.J., Lee J.W., Liao M.H., Shih W.L. Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. J Hepatol 2005, 42:520-527.
86. Lara-Pezzi E., Gomez-Gaviro M.V., Galvez B.G., Mira E., Iniguez M.A., Fresno M., et al. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 2002, 110:1831-1838.
87. Zhao XL, Sun T, Che N, Sun D, Zhao N, Dong XY, et al. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator twist1. J Cell Mol Med 2010.
88. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
89. Taras D., Blanc J.F., Rullier A., Dugot-Senant N., Laurendeau I., Vidaud M., et al. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol 2007, 46:69-76.
90. Qi J.H., Ebrahem Q., Moore N., Murphy G., Claesson-Welsh L., Bond M., et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003, 9:407-415.
91. Zhang H., Wang Y.S., Han G., Shi Y. TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721. Hepatobiliary Pancreat Dis Int 2007, 6:487-491.
92. Xia D., Yan L.N., Xie J.G., Tong Y., Yan M.L., Wang X.P., et al. Overexpression of TIMP-1 mediated by recombinant adenovirus in hepatocellular carcinoma cells inhibits proliferation and invasion in vitro. Hepatobiliary Pancreat Dis Int 2006, 5:409-415.
93. Kim J.R., Kim C.H. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells. Int J Biochem Cell Biol 2004, 36:2293-2306.
94. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995, 270:5331-5338.
95. Kinoshita T., Sato H., Okada A., Ohuchi E., Imai K., Okada Y., et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 1998, 273:16098-16103.
96. Mejean A., Lebret T. The metastatic cascade: angiogenesis and new concepts]. Prog Urol 2008, 18(Suppl 7):S156-S166.
97. El-Zayadi A.R. Heavy smoking and liver. World J Gastroenterol 2006, 12:6098-6101.
98. Wang S., Ai X., Freeman S.D., Pownall M.E., Lu Q., Kessler D.S., et al. QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci USA 2004, 101:4833-4838.
99. Uchimura K., Morimoto-Tomita M., Bistrup A., Li J., Lyon M., Gallagher J., et al. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem 2006, 7:2.
100. Lai J.P., Sandhu D.S., Yu C., Han T., Moser C.D., Jackson K.K., et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47:1211-1222.
101. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
102. Hossain M.M., Hosono-Fukao T., Tang R., Sugaya N., van Kuppevelt T.H., Jenniskens G.J., et al. Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. Glycobiology 2010, 20:175-186.
103. Liu C.J., Lee P.H., Lin D.Y., Wu C.C., Jeng L.B., Lin P.W., et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009, 50:958-968.
104. Aumailley M., Bruckner-Tuderman L., Carter W.G., Deutzmann R., Edgar D., Ekblom P., et al. A simplified laminin nomenclature. Matrix Biol 2005, 24:326-332.
105. Giannelli G., Fransvea E., Bergamini C., Marinosci F., Antonaci S. Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin Cancer Res 2003, 9:3684-3691.
106. Carter W.G., Kaur P., Gil S.G., Gahr P.J., Wayner E.A. Distinct functions for integrins alpha 3 beta 1 in focal adhesions and alpha 6 beta 4/bullous pemphigoid antigen in a new stable anchoring contact (SAC) of keratinocytes: relation to hemidesmosomes. J Cell Biol 1990, 111:3141-3154.
107. Giannelli G., Bergamini C., Fransvea E., Marinosci F., Quaranta V., Antonaci S. Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest 2001, 81:613-627.
108. Bergamini C., Sgarra C., Trerotoli P., Lupo L., Azzariti A., Antonaci S., et al. Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology 2007, 46:1801-1809.
109. Mizuno H., Ogura M., Saito Y., Sekine W., Sano R., Gotou T., et al. Changes in adhesive and migratory characteristics of hepatocellular carcinoma (HCC) cells induced by expression of alpha3beta1 integrin. Biochim Biophys Acta 2008, 1780:564-570.
110. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69:11-25.
111. Wu Y., Zuo J., Ji G., Saiyin H., Liu X., Yin F., et al. Proapoptotic function of integrin beta(3) in human hepatocellular carcinoma cells. Clin Cancer Res 2009, 15:60-69.
112. Fu Y., Fang Z., Liang Y., Zhu X., Prins P., Li Z., et al. Overexpression of integrin beta1 inhibits proliferation of hepatocellular carcinoma cell SMMC-7721 through preventing Skp2-dependent degradation of p27 via PI3K pathway. J Cell Biochem 2007, 102:704-718.
113. Ji J, Zhao L, Budhu A, Forgues M, Jia HL, Qin LX, et al. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol 52:690-7.
114. Cressman D.E., Greenbaum L.E., DeAngelis R.A., Ciliberto G., Furth E.E., Poli V., et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996, 274:1379-1383.
115. Tilg H., Wilmer A., Vogel W., Herold M., Nolchen B., Judmaier G., et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992, 103:264-274.
116. Wong V.W., Yu J., Cheng A.S., Wong G.L., Chan H.Y., Chu E.S., et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009, 124:2766-2770.
117. Nakagawa H., Maeda S., Yoshida H., Tateishi R., Masuzaki R., Ohki T., et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 2009, 125:2264-2269.
118. Zhu A.X., Sahani D.V., Duda D.G., di Tomaso E., Ancukiewicz M., Catalano O.A., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27:3027-3035.
119. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
120. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197-208.
121. Fausto N., Campbell J.S., Riehle K.J. Liver regeneration. Hepatology 2006, 43:S45-53.
122. Han Y.P., Zhou L., Wang J., Xiong S., Garner W.L., French S.W., et al. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 2004, 279:4820-4828.
123. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
124. Yamashita Y.I., Shimada M., Hasegawa H., Minagawa R., Rikimaru T., Hamatsu T., et al. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 2001, 61:1005-1012.
125. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997, 90:2541-2548.
126. Sangro B., Mazzolini G., Ruiz J., Herraiz M., Quiroga J., Herrero I., et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004, 22:1389-1397.
127. Coulouarn C., Factor V.M., Thorgeirsson S.S. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008, 47:2059-2067.
128. Hoshida Y., Nijman S.M., Kobayashi M., Chan J.A., Brunet J.P., Chiang D.Y., et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009, 69:7385-7392.
129. Chen X., Cheung S.T., So S., Fan S.T., Barry C., Higgins J., et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002, 13:1929-1939.
130. Lee J.S., Heo J., Libbrecht L., Chu I.S., Kaposi-Novak P., Calvisi D.F., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006, 12:410-416.
131. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359:1995-2004.
132. Budhu A., Forgues M., Ye Q.H., Jia H.L., He P., Zanetti K.A., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10:99-111.
133. Ye Q.H., Qin L.X., Forgues M., He P., Kim J.W., Peng A.C., et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003, 9:416-423.
134. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W.G., Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997, 277:225-228.
135. Koshikawa N., Giannelli G., Cirulli V., Miyazaki K., Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000, 148:615-624.
136. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.